Systemic Mastocytosis in a Patient with BCR-ABL1-Positive Chronic Myeloid Leukemia in the Remission Phase-Reference-Cited by-同舟云学术

Systemic Mastocytosis in a Patient with BCR-ABL1-Positive Chronic Myeloid Leukemia in the Remission Phase

Published:2022-11-03 Issue: Volume:2022 Page:1-3
ISSN:2090-6579
Container-title:Case Reports in Hematology
language:en
Short-container-title:Case Reports in Hematology

Author:

Fokoloros Christos¹^ORCID,Foukas Periklis²,Georgakopoulos Nikolaos³,Tsakiraki Zoi²,Bouchla Anthi⁴,Pappa Vasilliki⁴,Katoulis Alexandros¹,Makris Michael¹,Papageorgiou Sotirios³

Affiliation:

1. Allergy Unit “D. Kalogeromitros”, 2nd Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece

2. 2nd Department of Pathology, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece

3. Department of Cytogenetics and Molecular Pathology, Locus Medicus S.A., Athens, Greece

4. Hematology Unit, 2nd Department of Internal Medicine, Propaedeutic, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece

Abstract

Systemic mastocytosis (SM) comprises a group of rare disorders resulting from tissue infiltration by pathological mast cells. In a percentage ranging from 5 to 40% in various patient series, SM appears to be associated with an accompanying hematologic neoplasm (SM-AHN). The coexistence of SM with chronic myelogenous leukemia (CML) is extremely rare with only 3 cases in the literature. The natural course of CML has changed dramatically over the past 2 decades with the use of tyrosine kinase inhibitors (TKIs). We report a case of diagnosing SM in a patient in complete molecular remission of CML after stopping TKI treatment.

Publisher

Hindawi Limited

Subject

Cell Biology,Developmental Biology,Embryology,Anatomy

Link

http://downloads.hindawi.com/journals/crihem/2022/7251658.pdf

Reference7 articles.

1. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts

2. The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives

3. National comprehensive cancer network: NCCN guidelines version 2022;Chronic Myeloid Leukemia,2022

4. Systemic mastocytosis (SM) with associated BCR-ABL-positive myelogenous leukaemia (SM-AHNMD): evidence that mast cells do not belong to the leukaemic clone

5. Ph-Chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosis